2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial section
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceStructure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5
Mangou K, Moore A, Thiam L, Ba A, Orfanó A, Desamours I, Ndegwa D, Goodwin J, Guo Y, Sheng Z, Patel S, Diallo F, Sene S, Pouye M, Faye A, Thiam A, Nunez V, Diagne C, Sadio B, Shapiro L, Faye O, Mbengue A, Bei A. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Scientific Reports 2022, 12: 19403. PMID: 36371450, PMCID: PMC9653458, DOI: 10.1038/s41598-022-23929-9.Peer-Reviewed Original ResearchConceptsImmune evasionSingle nucleotide polymorphismsPopulation prevalenceVaccine-induced protective immunityP. falciparum positive samplesFalciparum positive samplesPlasmodium falciparum antigensMalaria vaccine candidateNovel single nucleotide polymorphismsInhibitory monoclonal antibodiesProtective immunityFalciparum antigensMalaria deathsEffective vaccineEfficacious vaccineVaccine candidatesPfRH5Infected individualsVaccine targetsMonoclonal antibodiesLow overall frequencyReceptor bindingNovel genetic variantsVaccineOverall frequencyClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definitionThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7
2021
Lessons Learned From COVID-19 Contact Tracing During a Public Health Emergency: A Prospective Implementation Study
Shelby T, Schenck C, Weeks B, Goodwin J, Hennein R, Zhou X, Spiegelman D, Grau LE, Niccolai L, Bond M, Davis JL. Lessons Learned From COVID-19 Contact Tracing During a Public Health Emergency: A Prospective Implementation Study. Frontiers In Public Health 2021, 9: 721952. PMID: 34490198, PMCID: PMC8417826, DOI: 10.3389/fpubh.2021.721952.Peer-Reviewed Original ResearchConceptsProspective implementation studyOutreach callsContact tracingAge-related disparitiesPublic health nursesRE-AIM implementation frameworkMultivariable regression modelsTimeliness of caseImplementation studyPublic health responsePublic health emergencyMedian timeHealth nursesAfrican American casesHealth responseInfectious diseasesFuture epidemicsDays of exposureHealth emergencyCOVID-19System-level predictorsRegression modelsCOVID-19 Contact TracingDaysPredictorsNew bullous lesions in a 72-year-old woman
Mendoza H, Goodwin J, Gehlhausen J, Odell I, McNiff J, Gnanapandithan K. New bullous lesions in a 72-year-old woman. Cleveland Clinic Journal Of Medicine 2021, 88: 319-324. PMID: 34078615, DOI: 10.3949/ccjm.88a.20180.Peer-Reviewed Case Reports and Technical NotesImplementation of a volunteer contact tracing program for COVID-19 in the United States: A qualitative focus group study
Shelby T, Hennein R, Schenck C, Clark K, Meyer AJ, Goodwin J, Weeks B, Bond M, Niccolai L, Davis JL, Grau LE. Implementation of a volunteer contact tracing program for COVID-19 in the United States: A qualitative focus group study. PLOS ONE 2021, 16: e0251033. PMID: 33951107, PMCID: PMC8099418, DOI: 10.1371/journal.pone.0251033.Peer-Reviewed Original Research
2020
Air embolism after peripheral IV contrast injection.
Goodwin J, Gnanapandithan K. Air embolism after peripheral IV contrast injection. Cleveland Clinic Journal Of Medicine 2020, 87: 718-720. PMID: 33229386, PMCID: PMC8048767, DOI: 10.3949/ccjm.87a.20001.Peer-Reviewed Original ResearchCommunity Trace: Rapid Establishment of a Volunteer Contact Tracing Program for COVID-19.
Niccolai L, Shelby T, Weeks B, Schenck C, Goodwin J, Hennein R, Rossini M, Vazquez J, van Rhijn D, Meek J, Bond M. Community Trace: Rapid Establishment of a Volunteer Contact Tracing Program for COVID-19. American Journal Of Public Health 2020, 111: 54-57. PMID: 33211580, PMCID: PMC7750620, DOI: 10.2105/ajph.2020.305959.Peer-Reviewed Original ResearchInvestigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso
Somé FA, Bazié T, Ehrlich HY, Goodwin J, Lehane A, Neya C, Zachari K, Wade M, Ouattara JM, Foy BD, Dabiré RK, Parikh S, Ouédraogo JB. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malaria Journal 2020, 19: 238. PMID: 32631416, PMCID: PMC7339464, DOI: 10.1186/s12936-020-03311-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDay 7 concentrationsSMC administrationMalaria chemopreventionMalaria infectionDay 7 plasma concentrationsHigh malaria transmission seasonBlood spotsFirst monthPfcrt 76TPrevalence of microscopicSubmicroscopic malaria infectionMalaria transmission seasonPlasmodium falciparum infectionPfcrt K76THigh transmission settingsSequential cross-sectional surveysCross-sectional surveyNon-significant trendAmodiaquine metabolismPfmdr1 N86Malaria parasitaemiaFalciparum infectionK76TPlasma concentrations
2019
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh MH, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M, Gerold H, Nowak C, Do H, Mazambani S, Knighton JK, Cha M, Goodwin J, Kang MK, Jeong JY, Lee SY, Faubert B, Xuan Z, Abel ED, Scafoglio C, Shackelford DB, Minna JD, Singh PK, Shulaev V, Bleris L, Hoyt K, Kim J, Inoue M, DeBerardinis RJ, Kim TH, Kim JW. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports 2019, 28: 1860-1878.e9. PMID: 31412252, PMCID: PMC7048935, DOI: 10.1016/j.celrep.2019.07.027.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsApoptosisCarcinoma, Squamous CellCell ProliferationFemaleGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1HumansMaleMembrane ProteinsMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesSignal TransductionSOXB1 Transcription FactorsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsSquamous cell carcinomaCell carcinomaInsufficient therapeutic optionsBlood insulin levelsRenal glucose reabsorptionBlood glucose concentrationTumor growth inhibitionAnti-oxidative capacityMultiple anatomical sitesPI3K/AktGlucose restrictionSCC patientsWorse survivalKetogenic dietInsulin levelsTherapeutic optionsCancer mortalityGlucose reabsorptionSCC tumorsBlood glucoseSCC cellsAnatomical sitesCancer typesMetabolic vulnerabilitiesOxidative stress
2018
Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
Do SK, Jeong JY, Lee SY, Choi JE, Hong MJ, Kang HG, Lee WK, Seok Y, Lee EB, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Neugent ML, Goodwin J, Kim JW, Park JY. Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer. Annals Of Surgical Oncology 2018, 25: 3396-3403. PMID: 30062472, DOI: 10.1245/s10434-018-6677-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerPrognosis of patientsCell lung cancerSingle nucleotide polymorphismsLung cancerStage non-small cell lung cancerSurvival of patientsSquamous cell carcinomaGlucose transporter 1 (GLUT1) geneBetter OSCurative surgerySurgical resectionWorse OSTumor histologyCell carcinomaStratified analysisBackgroundThis studyPatientsMultivariate analysisTransporter 1 geneConclusionsThis studyGene variantsPrognosisBad genotypes
2017
Targeting Hypoxia-Inducible Factor-1α/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis
Goodwin J, Choi H, Hsieh MH, Neugent ML, Ahn JM, Hayenga HN, Singh PK, Shackelford DB, Lee IK, Shulaev V, Dhar S, Takeda N, Kim JW. Targeting Hypoxia-Inducible Factor-1α/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2017, 58: 216-231. PMID: 28915065, PMCID: PMC5805994, DOI: 10.1165/rcmb.2016-0186oc.Peer-Reviewed Original ResearchConceptsPyruvate dehydrogenase kinase 1Myofibroblast differentiationPulmonary fibrosisFibrotic progressionHIF-1αGlycolytic metabolismDehydrogenase kinase 1Knockout mouse modelHypoxia-inducible factorMetabolic reprogrammingCellular metabolismPotential therapeutic strategyKinase 1Glycolytic switchGenomic deletionsSustained activationMicroenvironmental influencesPreclinical efficacyGlycolytic reprogrammingPharmacological inhibitionReprogrammingMouse modelDifferentiationPharmacological approachesTherapeutic strategiesThe distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications 2017, 8: 15503. PMID: 28548087, PMCID: PMC5458561, DOI: 10.1038/ncomms15503.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAnimalsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell Line, TumorCohort StudiesDeoxyglucoseFemaleFluorodeoxyglucose F18Gene Expression ProfilingGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1GlycolysisHumansHydroxybenzoatesLungLung NeoplasmsMaleMiceMice, NudeMiddle AgedPhenotypePositron-Emission TomographyPrognosisSurvival AnalysisUp-RegulationXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerSquamous cell carcinomaLung SqCCCell carcinomaNSCLC subtypesGlycolytic inhibitionLung squamous cell carcinomaCell lung cancerPatient-derived xenograftsNSCLC tumor samplesNSCLC cell linesCancer Genome AtlasClinical presentationPoor prognosisTherapeutic optionsLung cancerPredominant subtypeDistinct metabolic phenotypesSelective vulnerabilityLung adenocarcinomaMurine modelTherapeutic strategiesSqCCTumor samplesMetabolic signatures
2016
NQO1 inhibits proteasome-mediated degradation of HIF-1α
Oh ET, Kim JW, Kim JM, Kim SJ, Lee JS, Hong SS, Goodwin J, Ruthenborg RJ, Jung MG, Lee HJ, Lee CH, Park ES, Kim C, Park HJ. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nature Communications 2016, 7: 13593. PMID: 27966538, PMCID: PMC5171868, DOI: 10.1038/ncomms13593.Peer-Reviewed Original ResearchConceptsHIF-1αColorectal cancer patient survivalNQO1 expression levelsBreast cancer cell linesOverexpression of NQO1HIF-1α expressionCancer patient survivalPro-tumorigenic capacityNQO1 knockdownCancer cell linesPro-tumorigenic functionsPatient survivalPoor prognosisHIF-1α stabilityFunction of NQO1Oxygen-dependent domainHuman colorectalMalignant progressionTumor growthNQO1CancerHIF-1Human cancersMaster transcription factorExpression levels